UTHR insider trading
NasdaqGS HealthcareUNITED THERAPEUTICS Corp — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About UNITED THERAPEUTICS Corp
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company involved in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. United Therapeutics Corporation was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
Company website: www.unither.com
UTHR insider activity at a glance
FilingIQ has scored 7,444 insider transactions for UTHR since Aug 15, 2014. The most recent filing in our index is dated May 13, 2026.
Across the full history, 5 open-market purchases
and 4,709 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on UTHR insider trades is 67.0/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest UTHR Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
13F funds holding UTHR
Frequently asked
- How many insider trades does FilingIQ track for UTHR?
- FilingIQ tracks 7,444 Form 4 insider transactions for UTHR (UNITED THERAPEUTICS Corp), covering filings from Aug 15, 2014 onwards. 1,098 of those were filed in the last 90 days.
- Are UTHR insiders net buyers or net sellers?
- Across the full Form 4 history for UTHR, 5 transactions (0%) were open-market purchases and 4,709 (63%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does UTHR insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is UTHR in?
- UNITED THERAPEUTICS Corp (UTHR) is classified in the Healthcare sector, specifically Drug Manufacturers - Specialty & Generic, with a current market capitalisation of $21.46B.
Methodology & sources
Every UTHR insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.